<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-1-2">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>	
			</div>

			<div class="slide-title red">
				Phase II study in refractory aplastic anaemia: key endpoints
			</div>


			<div class="content-container">
				
				<table class="red">
					<tr>
						<th colspan="2">Laboratory tests</th>
					</tr>
					<tr class="odd" style="font-weight:bold">
						<td>Haematological parameter</td>
						<td>Definition</td>
					</tr>
					<tr>
						<td>Platelets</td>
						<td>
							Increase of ≥20,000 cells/mm3 from baseline<br /><br />

							OR <br /><br />

							Transfusion independence for ≥8 weeks in patients who were previously transfusion-dependent 
						</td>
					</tr>
					<tr class="odd">
						<td>Erythrocytes</td>
						<td>
							Increase in haemoglobin level (from a pre-treatment baseline of &lt;9 g/dl) by ≥1.5 g/dl without packed RBC transfusion<br /><br />

							OR<br /><br />


							Reduced number of packed RBC units transfused by ≥4 units for 8 consecutive weeks, compared with requirements during the 8 weeks before study entry

						</td>
					</tr>

					<tr>
						<td>Neutrophils</td>
						<td>Increase of ≥100% in absolute neutrophil count (ANC) in patients with a baseline value of &lt;500 cells/mm3 , or an ANC increase of >500 cells/mm3 in patients with pre-treatment ANC of ≥500 cells/mm<sup>3</sup></td>
					</tr>

				</table>

			</div>

		</div>


		<div class="information-overlay overlay">
			
			<header>Phase II study in refractory aplastic anaemia: key endpoints</header>
			
			<ul>
				<li><span>Secondary endpoints included: </span>
					<ul>
						<li><span>Changes in blood counts measured as continuous variables</span></li>
						<li><span>Bone marrow parameters: cellularity, haematopoiesis and morphological characteristics</span></li>
						<li><span>Metaphase cytogenetic profile</span></li>
						<li><span>Toxicity, as measured with the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3</span></li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/OlnesM-2012-NEJM-v367p11.pdf"><span>Olnes M <i>et al. N Engl J Med</i> 2012;367:11</span></li>
			</ul>

		</div>

	</div>
</div>